ArticleImmunology1995
Partial characterization of a circulating tolerogenic moiety which, after a feed of ovalbumin, suppresses delayed-type hypersensitivity in recipient mice.
Article in Immunology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 23 citations in OpenAlex.
- Tolerance and bystander suppression, with involvement of CD25-positive cells, is induced in rats receiving serum from ovalbumin-fed donors.Immunology · 2000Article
- Antigen-specific immunotherapy of autoimmune disease: a commentary.Clinical and experimental immunology · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum collected 60 min after feeding ovalbumin (OVA) to BALB/c mice transfers specific tolerance to naive recipients via an unknown mechanism. We have now identified a large fragment of the OVA molecule as the putative active moiety. Specific absorption of immunoreactive OVA from tolerogenic serum by immunoaffinity chromatography removed the tolerogenic activity; following elution of the bound OVA and subsequent injection into naive recipients it was possible to demonstrate tolerogenic activity equivalent to that seen with unmanipulated serum. Passage of OVA tolerogenic serum through a bovine serum albumin (BSA)-specific affinity column had no effect on in vivo OVA tolerogenic activity. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting using anti-OVA antibodies demonstrated the presence of two bands with apparent molecular weights (MW) of 21,000 and 24,000 in the OVA-related material absorbed from the tolerogenic serum. The 24,000 MW moiety was also visualized by silver staining. These moieties are putative candidate tolerogens as they were absent from normal BALB/c mouse serum analysed 5 min after feeding OVA and from severe combined immunodeficiency (SCID) mouse serum--without tolerising activity--analysed 60 min after a similar feed.
Indexed as
Identifiers
8550089PMC1383955W2416156335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.